PGG

Nectero Medical Announces Completion of $96M Series D Financing

Retrieved on: 
Thursday, April 11, 2024
Research, Medical Devices, Surgery, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Aphelion, Collagen, PGG, Phase, Investment, Safety, NDA, Food, AAA, Elastin, Patient, Boston Scientific, Medicine, General partnership, Venture round, Norwest Venture Partners, Breakthrough therapy, Medical device

Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round.

Key Points: 
  • Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round.
  • Upon completion of the Series D financing, Dr. Zack Scott, of Norwest Venture Partners, and Dr. Alan Davis, of BioStar Capital, have joined the Nectero Medical Board of Directors.
  • In January 2024, Nectero Medical initiated a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero EAST System in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm.
  • “We are honored and excited to be the lead investor in the Series D financing to fund the efforts necessary to bring the Nectero EAST System to market,” said Dr. Zack Scott, General Partner, Norwest Venture Partners.

Nectero Medical Announces Initiation of Phase II/III Clinical Trial of the Nectero EAST® System for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Rupture, Associate, EVAR, University, AAA, Risk, PGG, Division, Safety, Medicine, Hospital, Collagen, Clinical trial, Elastin, Growth, Pharmaceutical industry

The Nectero EAST System is a single-use, endovascular system comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG).

Key Points: 
  • The Nectero EAST System is a single-use, endovascular system comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG).
  • The system delivers PGG locally into the aneurysmal wall, where it can bind to elastin and collagen to potentially strengthen the aortic vessel wall and reduce the risk of further degradation.
  • “The Nectero EAST System aims to be the first proven early intervention therapy for small- to mid-sized AAA,” commented Jack Springer, President and Chief Executive Officer of Nectero Medical.
  • “Initiation of our randomized clinical trial is a significant milestone in our journey to bring this potentially transformative therapy to AAA patients.”

Nectero Medical Granted Breakthrough Therapy Designation for the Nectero EAST® System to Treat Infrarenal AAA

Retrieved on: 
Wednesday, November 1, 2023
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Food, Acanthosis nigricans, Fast Track, Agency, Medicine, Mortality, AAA, Rupture, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sudden death, Journal, Aneurysm, Growth, FIH, Breakthrough therapy, PGG, Safety, Patient, Pharmaceutical industry

Nectero Medical , a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm.

Key Points: 
  • Nectero Medical , a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm.
  • Breakthrough Therapy designation is an FDA program intended to facilitate design and conduct of an efficient product development program.
  • Nectero Medical’s Breakthrough Therapy designation is supported by results from the first-in-human (FIH) study (NCT05133492) of the Nectero EAST System.
  • “This designation reinforces Nectero Medical’s belief that the Nectero EAST System has the potential to have a significant impact for patients with AAA disease,” said Jack Springer, President and Chief Executive Officer of Nectero Medical.

Alcami Supports Phase II/III Trial Supply of the Nectero EAST® System

Retrieved on: 
Tuesday, October 17, 2023
Rupture, Food, Aortic aneurysm, Risk, IND, AAA, Elastin, PGG, Patient, CGMP, Growth, Journal, Collagen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDMO, Pharmaceutical industry, Medical device

Nectero Medical is developing a novel treatment to stabilize growth and potentially prevent rupture of smaller AAA.

Key Points: 
  • Nectero Medical is developing a novel treatment to stabilize growth and potentially prevent rupture of smaller AAA.
  • The Nectero EAST System is comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG).
  • "Nectero Medical is addressing the over 1,000,000 patients in the US with an AAA and currently no method of treatment.
  • Nectero EAST® is a registered trademark of Nectero Medical.

Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms

Retrieved on: 
Monday, July 24, 2023
PGG, Elastin, Vanderbilt University Medical Center, Professor, Investigational New Drug, Journal, Rupture, AAA, MD, Patient, Risk, Growth, Collagen, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, Food, Chair, Medical device, Pharmaceutical industry

TEMPE, Ariz., July 24, 2023 /PRNewswire/ -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study)  to evaluate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm. 

Key Points: 
  • "We believe the Nectero EAST® System has the potential to address a significant unmet clinical need and improve outcomes in AAA patients who currently have no proven treatment options.
  • Nectero EAST® aims to be the first therapy to stabilize growth of small- to mid-sized AAAs," commented Jack Springer, President and Chief Executive Officer of Nectero Medical.
  • The Nectero EAST® System is a single-use, endovascular system for the treatment of infrarenal abdominal aortic aneurysms and is comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG).
  • The stAAAble study will be conducted largely in the U.S. and is expected to initiate enrollment in the next few months.

Whistleblower to Receive $210,000 from $1M Government Customs Fraud Settlement with Samsung C&T America

Retrieved on: 
Monday, February 20, 2023
Defendant, District court, Accusative case, SCTA, Harmonized Tariff Schedule of the United States, Government, CBP, False Claims Act, U.S. Customs and Border Protection, Harmonized System, U.S. Immigration and Customs Enforcement, National Security Investigations Team (New Zealand), PGG, McInnis

NEW YORK, Feb. 20, 2023 /PRNewswire/ -- NYC whistleblower attorney Timothy J. McInnis announced that his client, Devyn Taylor, will receive $210,000 from the proceeds of a $1 million Government Customs fraud settlement with Samsung C&T America, Inc. ("SCTA"), a global trading and investment company.

Key Points: 
  • NEW YORK, Feb. 20, 2023 /PRNewswire/ -- NYC whistleblower attorney Timothy J. McInnis announced that his client, Devyn Taylor, will receive $210,000 from the proceeds of a $1 million Government Customs fraud settlement with Samsung C&T America, Inc. ("SCTA"), a global trading and investment company.
  • Taylor had previously filed under seal a qui tam whistleblower case pursuant to the False Claims Act against another party and that filing help lead to the Government's settlement with SCTA, according to McInnis.
  • The award to Ms. Taylor was also approved by J. Gardephe and publicly reported by the court on February 16, 2023.
  • The Government's case is captioned, United States of America, Plaintiff-Intervenor, v. Samsung C&T America, Inc., Defendant, 16 Civ.

BioHarvest Sciences Inc. Trademarks Its Breakthrough Non-GMO Proven Platform Technology: "BIO-PLANT CELLicitation"

Retrieved on: 
Wednesday, February 16, 2022
Intellectual property, CTO, PGG, Fruit, Company, Biotechnology, Dietary supplement, Terpene, Plant, Biomass, Canadian Securities Exchange, Polyphenol, BHSC, Technology, Functional food, Protein, Pomegranate, USD, Antioxidant, Trichome, Rehovot, Flow Science, Inc., CSE, Growth, Fine chemical, Medicinal plants, Cannabis, Cannabinoid

New name to reflect the Biotech power of combining plant cell growth with elicitation of specific molecules to produce unique compounds of high human utility value

Key Points: 
  • "The Bio-Plant CELLicitation proven platform technology allows us to address multiple market verticals with multiple products under different categories," said CEO Ilan Sobel.
  • The production in the industrial scale proprietary Bioreactors is done in aseptic conditions guaranteeing the highest levels of cleanliness.
  • BioHarvest recently announced that it produced a significant amount of Cannabis biomass without growing the plant itself, using the Bio-Plant CELLicitation platform technology.
  • BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange.

World's First Cryptocurrency Exchange To Accept PGG (Physical Gold) Pairing As A Medium Of Transfer

Retrieved on: 
Monday, August 27, 2018
Precious metals, Economy, Money, Currency, Cryptocurrency, London bullion market, Bullion, E-gold, PGG, Gold standard

OEX International Pte Ltd (Singapore) has collaborated with Puregold.sg Group to be the World's First Cryptocurrency Exchange to accept PGG (Physical Gold), pairing as a medium of transfer.

Key Points: 
  • OEX International Pte Ltd (Singapore) has collaborated with Puregold.sg Group to be the World's First Cryptocurrency Exchange to accept PGG (Physical Gold), pairing as a medium of transfer.
  • To acquire PGG (Physical Gold) through our Bullion Currencies platform, you may Signup at Bullion Currencies Gold Saving Account .
  • By pairing with PGG (Physical Gold), gold-backed token, it provides cryptocurrency exchange members an option to purchase PGG (Physical Gold) through our Bullion Currencies PG-Pay mobile platform, so they can instantly transfer PGG (Physical Gold) directly to the cryptocurrency exchange with the price set in LBMA gold price.
  • Cryptocurrency exchange members also have an option to sell their PGG (Physical Gold) by transferring it to PG-Pay mobile platform, without daily limitation.